To overcome the limitation of the short circulating half-life of small biotherapeutics, a large variety of half-life extension strategies have emerged in the last decades. The albumin-binding domain antibody (AlbudAb) was widely used to extend the half-lives of short-lived drugs.
For more: https://half-life-extension.cr....eative-biolabs.com/a
![image](https://ekcochat.com/upload/photos/2023/06/TxV4BYeD2koIYOaWQCSA_09_4b303c223d119f205ffe425d1e19e3d0_image.png)